L.L. Miller - Concepedia

Concepedia

Author

L.L. Miller

National Institutes of Health

Also Known As

L L Miller, L Miller, L. L. MILLER, L. L. Miller, L. Miller, L.L. Miller, Lei-Lani Miller

35

Publications

1.1K

Citations

13

H-Index

31

Concepts

All Affiliations

National Institutes of Health Mayo Clinic in Arizona National Cancer Institute PTC Therapeutics (United States)

LM

About

L.L. Miller is an author at National Institutes of Health specializing in medicine, pharmacology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	440
2	Immunology	3	3	238
3	Allergy	1	1	215
4	Molecular Biology	1	1	14
5	Pathology	1	1	11

L.L. Miller

×

15

Publications

1.1K

Citations

13

H-Index

	Year	Citations
Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Lynn E. S̄pitler, Maguy Del Rio, Archie Khentigan, PubMed Tumor ImmunologyAllergyAutoimmune DiseaseMetastatic Malignant MelanomaMild Allergic Reactions	1987	215
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Michael Wilschanski, L.L. Miller, David Shoseyov, European Respiratory Journal	2011	199
The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. John W. Smith, Walter J. Urba, Brendan D. Curti, Journal of Clinical Oncology	1992	166
Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer Stefanie A Jones, Charles L. Vogel, A. Arkhipov, Journal of Clinical Oncology	1999	113
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Henry C. Pitot, Richard M. Goldberg, Joel M. Reid, PubMed Prior Ap RadiationOncologyRadiation TherapyMetronomic TherapyPharmacology	2000	73
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma Charles D. Blanke, Daniel G. Haller, Al B. Benson, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicinePharmacologyPhase Ii Study	2001	58
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. Leonard B. Saltz, David R. Spriggs, Larry J. Schaaf, Journal of Clinical Oncology	1998	55
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks Mace L. Rothenberg, John G. Kuhn, Larry J. Schaaf, Annals of Oncology Pharmacological StudyPharmacologyPharmacokinetic TrialPharmacotherapyMedicine	2001	44
Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma John E. Janik, L.L. Miller, Daniele Longo, JNCI Journal of the National Cancer Institute	1996	30
Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. Peter J. O’Dwyer, F P LaCreta, Russell J. Schilder, Journal of Clinical Oncology	1992	29

Page 1